Clinical trials
Hematologic Diseases clinical trials
Below are recruiting hematologic diseases clinical trials, each written for real people, not researchers. We’re tracking 238 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07857746Recruiting
Outcomes of stem cell transplant in children
This study looks at how children who received a stem cell transplant at one hospital are doing. It aims to learn about their recovery and long-term results, which can help improve care for future patients.
Ratchathewi, BangkokAges Up to 18 years - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT07708987RecruitingPhase 2
Withaferin-A for steroid-resistant graft-versus-host disease
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
Navi Mumbai, MaharashtraAges 12–65 - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT06698211Enrolling by invitation
Posaconazole to prevent fungal infection in stem cell transplant patients with gut GVHD
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
TianjinAges 18–75 - NCT07305090Recruiting
Gut GVHD biomarker study for transplant patients
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
Bologna, BolognaAges 12 years+ - NCT06664541Enrolling by invitation
Gene therapy decisions and quality of life
This study looks at how people with blood diseases and their families make decisions about gene therapy, and how it affects their quality of life. It involves interviews or surveys to understand your experience.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07782684Recruiting
Recovery of immune cells after cord blood transplant
This study looks at how a type of immune cell called gamma-delta T cells recovers in your body after a cord blood transplant. It may help doctors understand how to improve recovery and reduce complications.
Hefei, AnhuiAges Any age - NCT02720679Recruiting
Study genetics behind blood disorders in children and families
This study looks at genetic (DNA) factors that may contribute to certain blood disorders. You may be invited if you or a close family member is receiving care for a blood condition like MDS or MPN, and the study also includes related relatives.
Memphis, TennesseeAges Any age - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT06477783Recruiting
Teclistamab and talquetamab for advanced multiple myeloma
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
Bonheiden, AntwerpenAges 18 years+ - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT05414045Recruiting
Transplanting your own frozen testicle tissue for future fertility
This trial studies transplanting frozen testicular tissue back into the body to help restore fertility later. It is meant for people who preserved testicular tissue as children before cancer or a blood disorder treatment.
BrusselsAges 18–50 - NCT07313059Recruiting
Clonal hematopoiesis study for people 55+
This study looks at a condition called clonal hematopoiesis (CH), where some blood cells have changes that may affect their health. It aims to prevent, treat, and better understand CH. You may qualify if you are 55 or older and have low blood counts that persist over time.
Canberra, Australian Capital TerritoryAges 55 years+ - NCT07257640RecruitingPhase 1
IL-5 CAR-T therapy for eosinophilic leukemia
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Hangzhou, ZhejiangAges 18 years+ - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT06534021RecruitingPhase 1
Study of IASO-782 for autoimmune blood disorders
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Wuhan, HubeiAges 18–65 - NCT06809712RecruitingPhase 1
Stem cell transplant from a partially matched unrelated donor
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
HangzhouAges 18–60 - NCT06809699RecruitingPhase 1
Stem cell transplant using a partially matched family donor
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hangzhou, ChinaAges 18–60 - NCT06281496Recruiting
Support for late effects after donor stem cell transplant
This trial offers support and guidance for people who have had a donor stem cell transplant and are managing long-term side effects. It aims to help you better handle late effects and improve your quality of life after transplant.
CopenhagenAges 18 years+ - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06222164Recruiting
Using leftover patient samples for research
This study uses leftover blood, bone marrow, or tissue samples that were already sent to a specific lab (LabPMM) for testing. Researchers want to study these samples to learn more about diseases and improve future tests for patients.
San Diego, CaliforniaAges 18 years+
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic diseases?
- Yes. Clin2 currently lists 238 recruiting hematologic diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.